

CHANGING THE WAY THE WORLD BREATHES

MASTER INVESTOR UK – 25th APRIL 2015

MICHAEL JOHNSON - CEO
SIR STEVEN REDGRAVE, CBE

FORWARD LOOKING STATEMENTS

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of RhinoMed Ltd to be materially different from the statements in this presentation.








Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of the Company's patent protection. RhinoMed does not undertake to update its forward-looking statements.

RADICALLY IMPROVE
THE WAY YOU BREATHE,
SLEEP,
MAINTAIN YOUR
HEALTH,
AND TAKE MEDICATION.


WHO IS **RHINOMED?** (RNO:AU)

- Early stage nasal and respiratory technology company based in Melbourne, Australia
- Rhinomed develops, markets and partners an internal nasal technology platform into multiple form factors
- Family of over 60 patents both granted and pending
- Market cap: AUD15m, early revenues from first two products
- Top 10 shareholders control approx. 25%
- Experienced team including deep biotech, commercialisation and global brand experience

ESTABLISHED CLINICAL PROGRAM

	Preclinical	Phase 1			Regulatory	In Market
OTC Dyspnoea in Sport and Exercise						<ul style="list-style-type: none">• FDA• CE Mark• Early Revenues
User Trial						
OTC Snoring and Sleep Quality						<ul style="list-style-type: none">• FDA• CE Mark• Early Revenues
	Preclinical	Phase 1	Phase 2	Phase 3	Regulatory	In Market
Sleep Apnea		Awaiting ethics approval				
Drug Delivery – Acute Migraine (sumatriptan)		Program Underway				
Hayfever - OTC						
Congestion - OTC						
Anxiety -OTC						

INITIAL STENTING CLINICAL TRIAL



Stenting the nose with the Rhinomed technology delivered an average of 642.8cc/sec **(37.6% increase)** in airflow through the nose

- Independent Phase One, proof of principle, clinical trial carried out at the Royal Victorian Eye & Ear Hospital
- Randomised cross over study (n=20) comparing the RNO001 technology against BreatheRight strips and baseline.

RHINOMED

ASX.RNO

USD32BILLION SPORTS AND NUTRITION MARKET
NOW HAS A NEW CATEGORY - BREATHING



BUY NOW AT www.theturbine.com

THE TURBINE

- Registered with US FDA, CE Mark, Australian TGA
- Starter pack containing 3 sizes - £9.85
- Refill 3 pack - £19.75 retail
- Approximately 10 uses per product (less than £1 a day)
- Optimizing and controlling airflow has advantages in sport and aerobic performance
- Sold on line and through sporting goods stores
- Shipping directly to consumers in over 36 countries since launch in January 2014
- New design began shipping mid February



BUY NOW AT
www.theturbine.com



CHRIS FROOME – 2013 WINNER OF THE TOUR DE FRANCE

HOW WELL DID YOU SLEEP LAST NIGHT?

RHINOMED

ASX.RNO

PREMIUM PROVEN PRODUCT ENTERING THE GLOBAL OTC SLEEP MARKET



GLOBAL DISTRIBUTION NOW ROLLING OUT


- Registered with US FDA, European Authority (CE Mark), Australian TGA
- Available as:
 - Starter pack containing 3 sizes
 - Refill pack in Small, Medium, Large
- Starter pack containing 3 sizes - £9.85
- Refill 3 pack - £19.75 retail
- Approximately 10 uses per product (less than £1 a day)
- Distribution
 - Sold online at www.mutesnoring.com
 - Ranged in Australia through Pharmacies
 - US online sales commencing
 - European online sales imminent
 - Pharmacy distribution in Europe and US 2015/16




SNORING AND POOR SLEEP IS A GLOBAL EPIDEMIC IMPACTING THE LIVES OF MILLIONS

SNORERS ARE CONCERNED ABOUT THEIR:


PHYSICAL WELLBEING



PRODUCTIVITY



RELATIONSHIP



- 45% of people in the UK snore
- 64% of American households have a snorer
- 77% of people in the UK believe nasal strips don't work.

THE UK HAS THE LOUDEST SNORER EVER RECORDED



- 111 decibels
- 8 decibels louder than a low flying jet

Jenny Chapman in 2009 courtesy of the Daily Mail

WE'VE JUST MUTED YOUR NATIONAL CHAMPION


"I've snored since I was five and over the years have tried pretty much everything. I've even considered surgery. The sound often wakes me up and most nights my husband Colin has to retreat to the spare room. I've tried Rhinomed's product Mu:te a few times now and haven't woken myself up once. My husband says my snoring is much reduced and much quieter, so I'm going to keep using it."

Jenny Chapman – April 2015

THE WORLD IS **SLEEP DEPRIVED**





1950: Arsenal win FA CUP
Average sleep – **9 hrs**



2014: Arsenal win FA CUP
Average - **6.5 hrs**



MUTE CAN IMPROVE SLEEP QUALITY



53% woke up feeling better

When using Mute users felt more rested in the morning and woke less at night.

Without Mute 47% reported feeling tired in the morning and 67% of waking a lot during the night

61% want to keep using Mute



OUR NEXT TARGET: **USD19 BILLION SLEEP APNEA MARKET**

Wisconsin Sleep Cohort Study (WSCS)			
	Classification	%	US Pop'n Prevalence
FEMALE	MILD	9%	14 million
	SEVERE	4%	6.2 million
MALE	MILD	24%	36.8 million
	SEVERE	9%	13.8 million

MILD/MODERATE
PATIENT COHORT
- 50.8 MILLION
PATIENTS

A 19 BILLION DOLLAR MARKET WITH A **MULTI-BILLION DOLLAR PROBLEM**



- **80%** OF THOSE WITH APNEA REMAIN UNDIAGNOSED
- **< 38%** COMPLIANCE RATES.
- **HIGH ENTRY COST** FOR TREATMENT.
- **FEW ALTERNATIVE TREATMENTS**
- **ALL HIGHLY INVASIVE** AND WITH LOW ACCEPTANCE.

NASAL STENTING AND VARIABLE STENTING PROGRAM


Stand alone EPAP therapy

- Variable stenting
- Increase air pressure during expiration (EPAP)
- Low invasive technology
- Targeting mild to moderate Sleep Apnea
- Trial at Monash University Medical Centre

Companion therapy

- Stenting nose during use of CPAP masks
- Stenting nose during use of Mandibular splints

INTRODUCING SCENT INTO THE PLATFORM



DECONGESTION

- ▶ Proprietary recipe of natural essential oils
- ▶ Decongestant
- ▶ Targeting use in sport and wellness


ANXIETY

- ▶ Relaxation and sleep problems
- ▶ Between 2006-11 OTC Sleep aids grew by 31%
- ▶ Proprietary recipe of natural essential oils

APPETITE MANAGEMENT

- ▶ Weight management market
- ▶ Direct to Consumer program
- ▶ Proprietary recipe of natural essential oils

DEVELOPING NEXT GENERATION NASAL CONGESTION SOLUTION



Source: Drug Store News; [JD 255222](#)

SIGNIFICANT OPPORTUNITY - ACUTE MIGRAINE



- **37 MILLION** AMERICANS SUFFER FROM MIGRAINE
- **< 25% ARE SATISFIED** WITH THEIR EXISTING THERAPY
- **US\$1.6 BILLION** - WORLDWIDE SALES OF IMITREX
- **EFFICACY AND SAFETY** ESTABLISHED
- **7,026,000** SUMATRIPTAN PRESCRIPTIONS

WHY INVEST?

- Sleep is a mainstream consumer health trend
- Drug Delivery is a major focus in pharma
- Attractive pipeline in billion dollar global markets with multiple revenue generating streams and clinical development program in Sleep and Drug Delivery
- Near term value milestones
 - OTC program rolling out
 - Clinical trials in sleep commencing
- Comparator M&A activity
 - 2007 – GSK acquire CNS (Breathe Right) for **US\$566 million**
 - 2007 - Phillips acquires Respirationics (CPAP masks) for **EU3.6 billion**

RNO:AU

CONTACT RHINOMED

Michael Johnson, CEO

mjohnson@rhinomed.com.au

+ 61 (0) 3 8416 0900

www.rhinomed.global